GPD2

Across TCGA pan-cancer cohorts, GPD2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of GPD2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where GPD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GPD2 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

PDAC, HNSC, and COAD are the cancer types where GPD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GPD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	II,III,IV	+0.497	<.001	10	view →
HNSC	All	II,III,IV	−0.377	<.001	10	view →
COAD	All	III,IV	+0.236	<.001	8	view →
LSCC	Male	III,IV	+0.301	<.001	6	view →
LUAD	All	All	+0.129	.001	3	view →
OV	All	All	+0.775	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

GPD2–PDAC

Open the PDAC breakdown →